News News Select Year All Years 2026 (23) 2025 (34) 2024 (29) 2023 (30) 2022 (33) 2021 (27) 2020 (34) 2019 (32) 2018 (42) 2017 (35) 2016 (43) 2015 (53) 2014 (26) 2013 (21) 2012 (16) 2011 (6) 2010 (4) 2009 (5) 2007 (1) 2006 (1) Search News Found 495 Results Page 44 of 50« First«...102030...4243444546...50...»Last » April 16, 2014 DBV Announces the First reported case of a long term sustained effect of Peanut desensitization after Epicutaneous Immunotherapy (EPITTM) with Viaskin® at the French Congress of Allergy April 16, 2014 CFA 2014 – Clinical Abstract April 15, 2014 DBV Technologies Announces Topline Financial Results for First Three Months 2014 April 9, 2014 DBV Technologies and CEA conclude a scientific cooperation to investigate epigenetic modulation in epicutaneous immunotherapy April 7, 2014 DBV Technologies Announces Creation of US Subsidiary and Appoints Ms. Susanna Mesa as Vice President of Finance, US Investor Relations & Strategy March 31, 2014 Additional Contribution to the Liquidity Agreement with Natixis March 25, 2014 DBV Announces Data Presentations for EPIT at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2014 March 17, 2014 DBV Technologies Reports Full Year 2013 Financial Results and Provides VIPES Update March 4, 2014 Presentation and Publication of Research at AAAAI Demonstrates EPITTM’s Ability to rebalance the Immune System and Induce a Disease-Modifying Effect February 18, 2014 DBV Technologies and Mount Sinai Hospital Enter Research Collaboration for Crohn’s Disease Page 44 of 50« First«...102030...4243444546...50...»Last »
